Navigation Links
Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
Date:8/28/2007

SEATTLE, Aug. 28 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) today announced that it had received a Deficiency Letter (the "Letter") from Nasdaq indicating that the Company's recently completed registered offering of Series C 3% Convertible Preferred Stock (the "Series C Preferred") and warrants did not comply with voting rights requirements set forth in Nasdaq Marketplace Rule 4351 and IM 4351. The Nasdaq staff verbally notified the Company of such noncompliance on August 9, 2007 and, in response to this verbal notification, the Company took action to cure the deficiency by amending the Articles of Amendment of the Company's Articles of Incorporation, which set forth the rights and preferences of the holders of the Series C Preferred (the "Articles of Amendment"). The amendment to the Articles of Amendment (the "Amendment") adjusted the conversion ratio of the Series C Preferred for purposes of the voting rights provision of the Articles of Amendment, and had the effect of reducing the number of votes that the holders of the Series C Preferred have because it increased the conversion price from $3.90 to $4.53 for purposes of the voting rights provision. The Amendment did not change the conversion price in any other provision of the Articles of Amendment, including but not limited to the provision on conversion of such Series C Preferred into shares of common stock.

The letter confirms that, subject to the public announcement requirements of Nasdaq Marketplace Rule 4803(a), the Company has regained compliance with Nasdaq Marketplace Rule 4351 and IM 4351 and the matter is now closed.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.cticseattle.com.

'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. Milwaukee takes another step in electronic patient data exchange
3. Ethics Board site offers welcome contrast to state IT mistakes
4. It takes more than money to reach the top
5. CATI takes tech transfer model national
6. Green economic plan takes cue from Indiana
7. Local software company takes Google to court over a patent
8. American Family CIO takes entrepreneurial approach to innovation
9. TDS takes top spot in region in customer satisfaction rankings
10. Innovative health care takes more than just IT automation
11. Centralization mania takes over
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)...   , ... zu KLOX    Mariano ... Officer bestellt    KLOX ist bestens ... zugelassenen Behandlungssystems zur Wundheilung zu beginnen    , ... sehr erfreut, die folgenden personellen Veränderungen anzukündigen: ...
(Date:11/21/2014)... , Nov. 21, 2014   TRU-D SmartUVC LLC ... their superbug-killing UVC automated disinfection robot, TRU-D SmartUVC, at FIS ... from Nov. 23 to 26 at Stand 23. ... United Kingdom,s largest infection-related event of ... societies to one of the leading events of its type ...
(Date:11/21/2014)... Offering a complete line of laboratory ... promotion . The Sartorius Entris Balance is the perfect ... and easy-to-maintain balance entry level balance. , The Entris ... to help customer’s bridge the gap between a basic ... very durable. Sartorius is the second biggest balance manufacturer ...
(Date:11/21/2014)... Palo Alto, Calif. (PRWEB) November 20, 2014 ... (CHI), a nonprofit, public policy research organization representing ... and pharmaceutical firms, and PwC US ... other states in life sciences industry growth. The ... and 2013. The 2015 California Biomedical Industry ...
Breaking Biology Technology:KLOX Technologies meldet Neubesetzung von Führungspositionen 2KLOX Technologies meldet Neubesetzung von Führungspositionen 3KLOX Technologies meldet Neubesetzung von Führungspositionen 4KLOX Technologies meldet Neubesetzung von Führungspositionen 5TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 2TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 3Pipette.com Announces an Extension on the Sartorius Entris Balance Promotion to the End of 2014 2California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 2California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 3California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 4
(Date:11/6/2014)... 2014 - Insilico Medicine, Inc, a Baltimore-based bioinformatics ... related diseases announced a research collaboration with the ... Oncology, Inc (OTC: CSBR). , "There are many ... but Champions Oncology,s TumorGraft technology is unique in ... regimen experimentally generating vast amounts of valuable data. ...
(Date:11/5/2014)... de Janeiro, Brazil -Individuals show great diversity in their ... males and females greatly differ in their perceptual evaluation ... of smell tests. , Sex differences in ... behaviors and may be connected to one,s perception of ... emotions. Thus, women,s olfactory superiority has been suggested to ...
(Date:11/4/2014)... Medicine announced today that it is a Grand ... Bill & Melinda Gates Foundation. Laura Goetzl, ... Sciences; and Vice Chair of Research and Academic ... pursue an innovative global health and development research ... Neurodevelopment.", Grand Challenges Explorations (GCE) funds individuals worldwide ...
Breaking Biology News(10 mins):Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2The female nose always knows: Do women have more olfactory neurons? 2Temple University School of Medicine receives Grand Challenges Explorations grant 2
... that can break down plant biomass into the precursors of ... to produce alternatives to petroleum. But the potential of this ... cannot break down lignin, a highly stable polymer that makes ... Streptomyces bacteria are among few microorganisms known to ...
... 14, 2013As scientists continue to unravel the complexity of the ... role in both normal physiology and disease, one particular class ... attention. Guest Editor Tom Cech, PhD and Executive Editor Fintan ... advancing research area in their Editorial " The (Noncoding) ...
... Studies at Le Bonheur Children,s Hospital in Memphis, ... RSV, replicate in humans, mutate to avoid the immune ... DeVincenzo, MD, medical director of Molecular Diagnostics and Virology ... Microbiology, Immunology, and Molecular Biology at The University of ...
Cached Biology News:A microbial biorefinery provides new insight into how bacteria regulate genes 2A microbial biorefinery provides new insight into how bacteria regulate genes 3Noncoding RNAs offer huge therapeutic and diagnostic potential 2Leading RSV researcher publishes work at Le Bonheur Children's 2Leading RSV researcher publishes work at Le Bonheur Children's 3
... 220 V, is used for agitation and mixing ... staining and destaining of gels and blots, and ... (8-40 rpm) and can handle a maximum load ... two 29 x 21 cm platforms covered with ...
...
...
... Wyatt Technology's family of light scattering instruments. ... temperature chromatograph and enables you to get ... The HTmD is easily installed in the ... Alliance 2000 device and enables you to ...
Biology Products: